Company: SRPT
Filing Date: 2025-01-13
Form Type: 8-K
Source: 0001193125-25-005160
Chunk: 0

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-01-13
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02 Results of Operations and Financial Condition.

On January 13, 2025, Douglas S. Ingram, President and Chief Executive Officer of Sarepta Therapeutics, Inc. (the “ Company”) disclosed certain preliminary financial information for the year ended December 31, 2024 during the Company’s presentation at the 43rd Annual J. P. Morgan Healthcare Conference (the “ Conference”) and in discussions with third parties at the Conference. Specifically, the Company disclosed its (unaudited) cash position of approximately $1.5 billion as of December 31, 2024, and that the Company generated approximately $1.79 billion in total net product revenue (unaudited) in the year ended December 31, 2024 and approximately $638 million in total net product revenue (unaudited) in the fourth quarter ended December 31, 2024, from sales of the Company’s four approved products, which includes: (i) approximately $254 million in net product revenue (unaudited) in the fourth quarter ended December 31, 2024 and approximately $967 million in net product revenue (unaudited) in the year ended December 31, 2024, each from sales of EXONDYS 51® (eteplirsen) Injection, VYONDYS 53® (golodirsen) Injection and AMONDYS 45® (casimersen) Injection, and (ii) approximately $384 million in net product revenue (unaudited) in the fourth quarter ended December 31, 2024 and approximately $821 million in net product revenue (unaudited) in the year ended December 31, 2024, each from sales of ELEVIDYS.

The Company also issued a press release disclosing such information on January 13, 2025. A copy of the press release is furnished with this report as Exhibit 99.1.

The information in this Item 2.02 is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2024 and its results of operations for the three months and year ended December 31, 2024. The audit of the Company’s financial statements for the year ended December 31, 2024 is ongoing and could result in changes to the information in this Item 2.02. Further, the information in this report, including Exhibit 99.1 attached